This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
by Zacks Equity Research
Small drugmakers, in general, are having a decent year, despite failures of key pipeline candidates in pivotal studies.
Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
by Zacks Equity Research
The CHMP postpones the review timeline of Portola's (PTLA) Ondexxya (in the EU. Shares take a hit.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.
Novan Announces Top-Line Data From Mid-Stage Molluscum Study
by Zacks Equity Research
Novan's (NOVN) nitric oxide candidate, SB206, demonstrates statistically significant reduction of lesions in patients with molluscum contagiosum.
Why Tilray (TLRY) Could Be Positioned for a Slump
by Zacks Equity Research
Tilray (TLRY) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Theravance Pipeline Strong, Plans Yupelri Launch by Year End
by Zacks Equity Research
Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.
Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase I study on novel JAK inhibitor, TD-8236, for treating serious respiratory diseases.
Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
by Zacks Equity Research
Theravance (TBPH) doses the first patient in a phase II Crohn's disease study on JAK inhibitor, TD-1473.
IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.
Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
TESARO (TSRO) Jumps: Stock Rises 5.4%
by Zacks Equity Research
TESARO (TSRO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
New Strong Buy Stocks for November 15th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioSpecifics (BSTC) delivered earnings and revenue surprises of 25.45% and 13.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
by Zacks Equity Research
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
BioSpecifics Technologies (BSTC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed Down After Clinical Hold on Two Early-Stage Studies
by Zacks Equity Research
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings
by Zacks Equity Research
Zacks.com highlights: OptimizeRX, Verso, BioSpecifics Technologies and Luxfer Holdings
BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
BioLineRx (BLRX) shares rose nearly 8% in the last trading session, amid huge volumes.
Champions Oncology (CSBR) Soars: Stock Adds 10.7% in Session
by Zacks Equity Research
Champions Oncology (CSBR) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
4 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Infinity Pharmaceuticals (INFI) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BSTC) Outperforming Other Medical Stocks This Year?
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Aldeyra Therapeutics (ALDX) shares rose nearly 8% in the last trading session, amid huge volumes.